

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy  
ID6470**

**Provisional Stakeholder List**

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Alnylam Pharmaceuticals (vutrisiran)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Amyloidosis UK</li> <li>• Arrythmia Alliance</li> <li>• Atrial Fibrillation Association</li> <li>• British Liver Trust</li> <li>• Cardiomyopathy UK</li> <li>• Cardiovascular Care Partnership</li> <li>• Gene People</li> <li>• Genetic Alliance UK</li> <li>• HEART UK</li> <li>• Liver4Life</li> <li>• Pumping Marvellous</li> <li>• Somerville Foundation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Genetic Nurses and Counsellors</li> <li>• British Cardiovascular Society</li> <li>• British Geriatrics Society</li> <li>• British Society for Gene and Cell Therapy</li> <li>• British Society for Genetic Medicine</li> <li>• National Heart and Lung Institute</li> <li>• Primary Care Cardiovascular Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Inherited Metabolic Disease Service</li> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Association of Renal Industries</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Cell and Gene Therapy Catapult</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• National Services Division</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Government</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Pfizer (tafamidis)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Circulation Foundation</li> <li>• Cochrane Heart Group</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> </ul>

Provisional stakeholder list for the evaluation of vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy ID6470

Issue date: October 2024

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• UK Clinical Pharmacy Association</li> <li>• Vascular Society of Great Britain and Ireland</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	<ul style="list-style-type: none"> <li>• National Centre for Cardiovascular Preventions and Outcomes</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare

Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.